Your browser doesn't support javascript.
loading
Bevacizumab for Retinopathy of Prematurity: 2-Year Neurodevelopmental Follow-up.
Zayek, Michael; Parker, Kaitlyn; Rydzewska, Monika; Rifai, Aref; Bhat, Ramachandra; Eyal, Fabien.
Affiliation
  • Zayek M; Division of Neonatology, Department of Pediatrics, University of South Alabama, Mobile, Alabama.
  • Parker K; Division of Neonatology, Department of Pediatrics, University of South Alabama, Mobile, Alabama.
  • Rydzewska M; Department of Pediatrics, Neonatal Medicine, Crozer-Keystone Health System, Upland, Pennsylvania.
  • Rifai A; Retina Center of Pensacola, Pensacola, Florida.
  • Bhat R; Division of Neonatology, Department of Pediatrics, University of South Alabama, Mobile, Alabama.
  • Eyal F; Division of Neonatology, Department of Pediatrics, University of South Alabama, Mobile, Alabama.
Am J Perinatol ; 38(11): 1158-1166, 2021 09.
Article in En | MEDLINE | ID: mdl-32446264
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Retinopathy of Prematurity / Child Development / Angiogenesis Inhibitors / Laser Therapy / Bevacizumab Type of study: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Child, preschool / Female / Humans / Infant / Male / Newborn Language: En Journal: Am J Perinatol Year: 2021 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Retinopathy of Prematurity / Child Development / Angiogenesis Inhibitors / Laser Therapy / Bevacizumab Type of study: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Child, preschool / Female / Humans / Infant / Male / Newborn Language: En Journal: Am J Perinatol Year: 2021 Type: Article